Cell and gene therapies are fundamentally different than traditional medicines, from the patient and product journeys to the systems and supply chain that support it.

These personalized medicines move through development at a faster pace than traditional drugs, with some reaching approval within four to five years from first-in-human trials. Bringing personalized medicine to market successfully, such as cell and gene therapies, requires industry expertise and a rigorous control process, coupled with advanced technology. Here, in this paper, we outline current challenges, their solutions, and a framework for how to choose a strategic partner in cell and gene therapy supply chain solutions.

You can rely on us as your personalized medicine supply chain partner because we are a wholly owned subsidiary of UPS and the essential clinical part of UPS Healthcare. With Marken, BOMI Group, and Polar Speed included, the UPS Healthcare network staffs 199 locations with 10,000+ employees worldwide.

To read our complete white paper, Solving Complexities In the Era Of Personalized Medicine Supply Chain, request a copy below.